Liepe K, Kropp J, Hliscs R, Franke W G
University Hospital, Department of Nuclear Medicine, Dresden, Germany.
Clin Nucl Med. 2000 Nov;25(11):901-4. doi: 10.1097/00003072-200011000-00009.
A 59-year-old man with prostate cancer and pain from multiple bone metastases was treated with 1,424 MBq (38.5 mCi) rhenium-186 hydroxyethylidene diphosphonate (Re-186 HEDP). In addition, he had nonsteroidal antiandrogen, progestagen, and an analog-luteinizing hormone. Neither chemotherapy nor external-beam radiotherapy was administered. Bisphosponate therapy was stopped 4 weeks before the administration of Re-186 HEDP. The Tc-99m HMDP whole-body scan obtained 6 weeks after therapy showed the same results as before therapy. However, 1 year after therapy, a significant reduction of the mass of the metastases was visible on bone scan. The bone scan index decreased from 34 before therapy to 10 after 1 year. The patient described significant pain relief and stopped his analgesic intake 3 weeks after therapy.
一名59岁患有前列腺癌且因多处骨转移而疼痛的男性患者，接受了1424兆贝克勒尔（38.5毫居里）的铼-186羟基亚乙基二膦酸盐（Re-186 HEDP）治疗。此外，他还服用了非甾体类抗雄激素药物、孕激素以及一种促黄体生成素类似物。既未进行化疗也未实施外照射放疗。在给予Re-186 HEDP治疗前4周停用了双膦酸盐治疗。治疗后6周进行的锝-99m亚甲基二膦酸盐（Tc-99m HMDP）全身扫描结果与治疗前相同。然而，治疗1年后，骨扫描显示转移灶的肿块明显缩小。骨扫描指数从治疗前的34降至1年后的10。患者称疼痛明显缓解，并在治疗3周后停止服用镇痛药。
